Windward Bio raised a $165 million crossover financing to move its long-acting anti-TSLP antibody into Phase 3 for asthma. The Swiss biotech is positioning its drug for twice-yearly dosing as a potential differentiator in a crowded respiratory market, where competitors are increasingly pushing longer intervals and combination profiles. The financing supports late-stage execution and suggests the company is targeting a clinical package designed for convenience plus efficacy in a chronic disease setting. For investors, it also signals confidence that next-generation biologics can still differentiate on administration schedules. The move follows broader late-stage funding patterns for respiratory monoclonals, where dosing frequency can translate directly into adherence and health-system uptake.